On Friday, April 5, 2024, the Renal Lifecycle symposium took place in Utrecht, the Netherlands. The symposium covered the state of the
Investigating the protection of heart and kidneys in patients with severe kidneyfailure
Welcome to the website of the Renal Lifecycle Trial
With this website, we aim to inform you about the Renal Lifecycle study. This website is intended for participants, professionals, and anyone else who is interested. Here you will find general information, newsletters, updates on the progress, and the current state of affairs. By using the headings at the top, you can navigate to the various topics. You can also contact the study team via the contact page or leave messages on the feedback page.
Informative
End of inclusion
As of 1 October 2026, enrolment for this study has closed. This means that we are no longer accepting new participants. The reason for this is that we have already far exceeded the number of participants required to generate robust and reliable study results. In fact, we have enrolled more than 1,800 participants! We would like to extend our sincere thanks to everyone involved in making this study a success: all the patients who have chosen to participate, as well as the physicians, research staff, and other team members who work hard to ensure that the study runs smoothly and successfully. Your commitment and support are greatly appreciated.
Start Spanje and Singapore
As mentioned previously, Spain and Singapore also expressed interest in participating in the study. We are pleased to report that in both countries the first patients have now been screened or already randomized. This brings us closer to the number of participants we aim for, namely 1,750.
International patient advisory board
Because we consider it important that patients have a voice and can participate in decision-making within the study, a Patient Advisory Board was established. Initially, this board consisted solely of Dutch patients. However, as the study is now being conducted in many more countries, and as patients' priorities and the most effective logistical approaches may differ between countries, our Patient Advisory Board has since become international. With the addition of participants from Spain, Germany, Belgium, and Australia, we are better able to address diverse preferences, needs, and cultural practices. Every three months, an online meeting is held between these members and the Groningen study team to discuss ongoing developments and provide feedback. The new members will introduce themselves in upcoming newsletters.
Timeline
October 2026 Stop inclusion |
September 2026 1800 Participants! |
January 2026 First participant screened in Singapore |
November 2025 1500 participants included worldwide |
October 2025 First participant included in Spain |
Participating centers worldwide
0
Numbers of participants worldwide
Below is an overview of participants so far from study start. On the bottom bar the time, on the left bar the number of participants randomized. The colors indicate the countries involved. The numbers are participants from all patient subgroups in all participating centers in that country added up.
Here is an overview of the participants by subgroup. The colors indicate which subgroup is involved. The numbers are participants of all patients in that subgroup from all participating countries added up.
News
The Renal Lifecycle research has made national television! In a broadcast of the program Koffietijd (on 28-10-2022) Professor Ron Gansevoort gave information
The October issue of Wisselwerking, the membership magazine of the NVN, features an interview with Drs. Heleen Nijmeijer, trial coordinator of the